These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10613317)

  • 1. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
    D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Tomaszewski JE; Wein A
    Cancer; 2000 May; 88(9):2110-5. PubMed ID: 10813723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing patient selection for prostate monotherapy.
    Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA Cheng GC; Chen MH; Whittington R; Malkowicz SB; Schnall MD; Tomaszewski JE; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):64-70. PubMed ID: 12504037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Tomaszewski JE; Wein A; Coleman CN
    Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):335-40. PubMed ID: 9308936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
    Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
    Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
    Valicenti RK; Chervoneva I; Gomella LG
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
    D'Amico AV; Renshaw AA; Arsenault L; Schultz D; Richie JP
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):841-6. PubMed ID: 10571187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Fondurulia J; Chen MH; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Coleman CN
    J Clin Oncol; 1999 Jan; 17(1):168-72. PubMed ID: 10458230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.